Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Diabetes Care|April 11, 2019
A Lack of Decline in Major Nontraumatic Amputations in Texas: Contemporary Trends, Risk Factor Associations, and Impact of RevascularizationMarlene Garcia, Brian Hernandez, Tyler G Ellington, et al.
Organelle (Tucson, Ariz.)|April 2, 2025
Robust assembly of electron transfer chain in the brain of naked mole-rats during agingTing Liang, Belinda Bernal, Wenbo Qi, et al.
Journal of Geriatric Oncology|February 4, 2014
An evaluation of elderly patients (≥70 years old) enrolled in Phase I clinical trials at University of Texas Health Science Center at San Antonio-Cancer Therapy Research Center from 2009 to 2011Julie Rowe, Sukeshi Patel, Marcela Mazo-Canola, et al.
Plastic and Reconstructive Surgery|August 25, 2021
Case Volume-Dependent Changes in Operative Morbidity following Free Flap Breast Reconstruction: A 15-Year Single-Center AnalysisOscar Ochoa, Steven Pisano, Peter Ledoux, et al.
British Journal of Cancer|June 23, 2022
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)Sukeshi Patel Arora, Laura Tenner, John Sarantopoulos, et al.
Urology|August 12, 2019
Chemoradiation Vs Radical Cystectomy for Muscle-invasive Bladder Cancer: A Propensity Score-weighted Comparative Analysis Using the National Cancer DatabaseDharam Kaushik, Hanzhang Wang, Joel Michalek, et al.
Cureus|February 15, 2019
The Impact of Marijuana Legalization on Vehicular TraumaNatash Keric, Luke J Hofmann, Rachelle Babbitt-Jonas, et al.
The Journal of Trauma and Acute Care Surgery|September 26, 2013
Characterizing vasopressin and other vasoactive mediators released during resuscitation of trauma patientsStephen M Cohn, Mark DeRosa, Janet McCarthy, et al.
Investigational New Drugs|January 20, 2017
Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?Christos Fountzilas, Selena Stuart, Brian Hernandez, et al.
Scientific Reports|January 28, 2021
Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastomaAndrew J Brenner, John Floyd, Lisa Fichtel, et al.
Pageof 7